What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Breast cancer
His primary areas of investigation include Internal medicine, Breast cancer, Oncology, Cancer and Chemotherapy.
His Endocrinology research extends to the thematically linked field of Internal medicine.
His Breast cancer research includes elements of Randomized controlled trial, Surgery and Pathology.
His Oncology research integrates issues from Trastuzumab, Metastatic breast cancer, Docetaxel, Bevacizumab and Adjuvant therapy.
His Cancer study combines topics from a wide range of disciplines, such as Disease, Immunology and Exome.
His study focuses on the intersection of Chemotherapy and fields such as Clinical endpoint with connections in the field of Clodronic acid and Placebo.
His most cited work include:
- Comprehensive molecular portraits of human breast tumours (7253 citations)
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer (804 citations)
- The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. (767 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Oncology, Breast cancer, Metastatic breast cancer and Cancer.
His research links Surgery with Internal medicine.
His Oncology research incorporates themes from Bevacizumab, Triple-negative breast cancer and Taxane.
His Breast cancer research is multidisciplinary, incorporating elements of Cancer research, Clinical trial, Pathology, Gynecology and Adjuvant therapy.
He focuses mostly in the field of Metastatic breast cancer, narrowing it down to matters related to Capecitabine and, in some cases, Docetaxel.
As part of his studies on Cancer, Adam Brufsky often connects relevant areas like Cohort.
He most often published in these fields:
- Internal medicine (74.96%)
- Oncology (65.83%)
- Breast cancer (61.54%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (74.96%)
- Oncology (65.83%)
- Breast cancer (61.54%)
In recent papers he was focusing on the following fields of study:
Adam Brufsky mainly focuses on Internal medicine, Oncology, Breast cancer, Metastatic breast cancer and Cancer.
His study in Oncology is interdisciplinary in nature, drawing from both Letrozole, Clinical endpoint, Triple-negative breast cancer and Phases of clinical research.
Neoadjuvant therapy is closely connected to Adjuvant in his research, which is encompassed under the umbrella topic of Breast cancer.
His Metastatic breast cancer research is multidisciplinary, relying on both Cancer research, Fulvestrant, Tyrosine-kinase inhibitor and Hazard ratio.
Adam Brufsky regularly links together related areas like Overall survival in his Cancer studies.
The various areas that Adam Brufsky examines in his Chemotherapy study include Taxane, Disease and Anthracycline.
Between 2019 and 2021, his most popular works were:
- Distinct viral clades of SARS-CoV-2: Implications for modeling of viral spread. (78 citations)
- Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic. (77 citations)
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study (56 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His scientific interests lie mostly in Internal medicine, Virology, Breast cancer, Oncology and Metastatic breast cancer.
He combines subjects such as Immunology, Pathogenesis and Virulence with his study of Virology.
His Breast cancer research includes themes of Regimen and Chemotherapy regimen.
His research integrates issues of Previously treated, Sacituzumab govitecan, Triple-negative breast cancer and Prostate cancer in his study of Oncology.
His study with Metastatic breast cancer involves better knowledge in Cancer.
His work on Fulvestrant, Palbociclib and Letrozole as part of general Cancer research is frequently linked to Clinical Practice, thereby connecting diverse disciplines of science.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
